Abiopharma

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Castle Biosciences - Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference